Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.
What Happened: Eli Lilly and Novo Nordisk (NYSE:NVO) are reportedly getting ready to unveil new pricing agreements with the White House for their popular weight loss drugs. In exchange, the companies could see those treatments covered under Medicare, according to sources cited by Max Bayer at Endpoints News.
